Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS3-007a SAD, MAD, and Food Effect Study in Healthy Adults
NCT07473570Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GS3-007 (6 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 21 days. Started Jan 2026; status: completed.
02
Drugs
GS3-007
Beyond the preview
Go deeper on NCT07473570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473570.